ALLMedicine™ Glucagon Center

Dec 2nd, 2021 - The goals of diabetes care are to prevent complications and optimize quality of life. Based on the goals, several strategies have developed and are still evolving for the pharmacological management of type 2 diabetes. In the last decade, various n...

Dec 1st, 2021 - Glucagon-like peptide-1 receptor agonists do not decrease the risk of coronary revascularization in patients with type 2 diabetes.|2021|Patoulias D,Papadopoulos C,Kassimis G,Doumas M,|

Nov 30th, 2021 - Dementias, including the type associated with Alzheimer's disease (AD), are on the rise worldwide. Similarly, type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic diseases globally. Although mechanisms and treatments are well-estab...

Nov 30th, 2021 - Long-term sleep deprivation (SD) is a bad lifestyle habit, especially among specific occupational practitioners, characterized by circadian rhythm misalignment and abnormal sleep/wake cycles. SD is closely associated with an increased risk of meta...

Nov 30th, 2021 - Konjac is a food mainly consumed in Asian countries with high fiber and low energy. Although glucomannan, a component of konjac, have been used for several clinical studies, there is few reports using konjac itself. This study examined the effects...

Jul 13th, 2020 - Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeuti...

Dec 21st, 2019 - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials...

Oct 7th, 2018 - The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation ...

Nov 18th, 2021 - The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years. Blood tests will be performed to check how ...

Nov 18th, 2021 - The current study is designed to test the feasibility of the a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults and children with cystic fibro...

Nov 17th, 2021 - Obesity is a worldwide problem to public health, with a prevalence rate of 12.4% according to recent studies. It is associated with a series of chronic non-communicable diseases, including type 2 diabetes, cardiovascular diseases, non-alcoholic fa...

Nov 17th, 2021 - REMD-477 (Volagidemab) is a human anti-glucagon receptor antibody. Its proposed mechanism of action in controlling hyperglycemia is by blocking glucagon receptor (GCGR) signaling. In this way, it increases hepatic glucose uptake, decreases hepatic...

Nov 15th, 2021 - This clinical trial will uncover new mechanisms of inter-individual responses to endogenous and exogenous glucagon-like peptide-1 (GLP-1) in Hispanics/Latinos (H/Ls) with prediabetes. The results move the management of prediabetes, type 2 diabetes...

Nov 18th, 2021 - The investigational long-acting amylin analogue cagrilintide (AM833) helped people with overweight or obesity, but no diabetes, shed pounds in a phase II trial. In the randomized trial, all doses of the novel once-weekly injectable treatment yield...

Nov 11th, 2021 - The STEP 5 clinical trial extends favorable weight loss from 1 year out to 2 years for the glucagon-like peptide-1 (GLP-1) agonist semaglutide (Wegovy, Novo Nordisk), given as a once-weekly 2.4-mg subcutaneous injection, and some food cravings wer...

Nov 5th, 2021 - Joyce O’Shaughnessy, MD: I’d love to hear from everybody what your personal experience has been with alpelisib. We also want to touch on toxicity so we can weave together a little bit of your personal experience efficacy-wise—which patients, where...

Oct 28th, 2021 - The "twincretin" tirzepatide scored another pivotal-trial win in full, published results from the multicenter SURPASS-4 trial, which compared the investigational agent to insulin glargine for treatment of type 2 diabetes. The study comprised 1,995...

Oct 6th, 2021 - (Reuters) - A recently recalled batch of Glucagon Emergency Kits, Eli Lilly and Co's therapy for diabetic patients in crisis, was manufactured at an Indiana factory cited by U.S. health regulators this year for quality-control violations, includin...